The Just MS (Multiple Sclerosis) Show

Send us Fan Mail

This week on Just MS News, we look at four developments in multiple sclerosis research and diagnosis — including an important FDA regulatory milestone for CAR-T therapy in progressive MS.

This week:

🔶 CAR-T for non-active SPMS
The FDA has granted RMAT designation to miv-cel, an experimental CD19 CAR-T therapy being studied in non-active secondary progressive MS. The designation could help accelerate its development — but it is not FDA approval, and the human evidence remains very early.

🔶 New 2024 McDonald Criteria
Updated MS diagnostic criteria may allow more people to meet diagnostic criteria earlier. One major change is the inclusion of the optic nerve as a fifth location when evaluating dissemination in space.

🔶 Lucid-MS moves toward Phase 2
Lucid-MS has been cleared to begin Phase 2 testing in progressive MS. The experimental therapy takes a different approach by targeting biological processes associated with myelin damage. Human evidence of benefit in MS has not yet been established.

🔶 Artificial Axons and remyelination research
Researchers are developing engineered artificial-axon models that may provide a better way to test potential remyelination drugs before they move toward human trials. This is a drug-discovery platform — not an MS treatment.

Related research: Last week, Just MS News covered lab-grown “mini-brains” being used to study myelin repair. This week’s Artificial Axons story tackles a similar problem from a different direction — using engineered nerve-fibre models to test how oligodendrocytes form myelin and how candidate remyelination drugs behave.

Together, they highlight a broader challenge in MS research: building better laboratory models before potential treatments move into human trials.

Sources:

1. CAR-T / miv-cel
   • Title: Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
   • Author/Source: Kyverna Therapeutics 
   • Published: August 11, 2026 
   • Live link: https://ir.kyvernatx.com/news-releases/
   •  This is the company release announcing that FDA granted RMAT designation to miv-cel for non-active SPMS. 
2. 2024 McDonald Criteria / Earlier MS Diagnosis
   • Title: Applying the 2024-revised McDonald criteria for multiple sclerosis using conventional diagnostic tools: a single-centre prospective cohort study in Germany
   • Lead author: F. F. Konen 
   • Journal: eClinicalMedicine 
   • DOI: 10.1016/j.eclinm.2026.104098 
   • Live link: https://www.sciencedirect.com/science/article/pii/S2589537026003512
   •  This is the 215-person study behind the 93.5% vs 84%, optic-nerve 55%, and VEP 89% figures. 
3. Lucid-MS / Phase 2
   • Title: FDA Clears Phase 2 Trial for Demyelinating Agent Lucid-MS in Progressive Multiple Sclerosis
   • Author: Marco Meglio 
   • Outlet: NeurologyLive 
   • Published: August 13, 2026 
   • Live link: https://www.neurologylive.com/view/fda-clears-phase-2-trial-demyelinating-agent-lucid-ms-progressive-multiple-sclerosis
   •  The article covers the FDA-cleared IND, Phase 1 healthy-volunteer results, PAD2 mechanism, and planned randomized Phase 2 trial. 
4. Artificial Axons / Remyelination Drug Screening
   • Title: MIT spinout Artificial Axon gets NINDS backing for MS lesion-mimicking drug screening platform
   • Source: AllSci 
   • Published: August 11, 2026 
   • Live link: https://allsci.com/news/grants/ms-drug-screening-platform-artificial-axon-labs/
   •  This is the source reporting the $1.48 million NINDS SBIR Phase II funding. 

For the Artificial Axon science itself, the underlying 2025 paper is also worth linking:

Myelin ensheathment and drug responses of oligodendrocytes are modulated by stiffness of artificial axons
Mingyu Yang, Calliope J. L. Martin, Kavin Kowsari, Anna Jagielska, Krystyn J. Van Vliet
PLOS ONE, 2025

The goal of Just MS News is simple: explain what happened, what the evidence actually shows, and why it matters for people living with MS.

Subscribe for weekly MS research, treatment and community news.

The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.

www.justmultiplesclerosis.com

Send us Fan Mail

This week on Just MS News, we take a closer look at three important stories from the multiple sclerosis community.

First, new research in JAMA Neurology strengthens the evidence around GFAP, a blood biomarker that may help researchers track progression independent of relapse activity, or PIRA. The study included more than 2,300 people with MS and over 18,000 blood measurements.

That story also connects with a small randomized study of high-dose N-acetyl cysteine, or NAC, in progressive MS. Participants received 1,250 mg three times daily for four weeks, and researchers observed a significant difference in GFAP levels compared with placebo. The study was very small and does not show that NAC slows MS progression, but a larger trial is already underway.

Next, we review a systematic review of exercise in people with severe MS disability. What can exercise still improve when walking is limited or disability has progressed, and why are nonambulatory people still so underrepresented in exercise research?

Finally, Christina Applegate is reportedly back home and doing very well following a months-long hospitalization. Applegate has been living publicly with MS since announcing her diagnosis in 2021.

Just MS News looks beyond the headline to explain what the research actually found, what remains uncertain, and why it may matter to people living with MS.

Sources include JAMA Neurology, Multiple Sclerosis Journal, Multiple Sclerosis and Related Disorders, University of Basel, UCSF, Neurology Advisor, and PEOPLE.

Learn more and follow the latest MS news at:
www.justmultiplesclerosis.com

This content is for news and educational purposes and is not medical advice.

The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.

www.justmultiplesclerosis.com

Send us Fan Mail

This Week on Just MS News

This week, we look at three important stories affecting the MS community.

Researchers in Australia are using lab grown “mini brains” to investigate how damaged myelin might one day be repaired. Sheffield Teaching Hospitals has also treated its first MS participant with experimental CAR T cell therapy, an approach researchers have been watching for years.

We also examine a revised Cleveland Clinic protocol designed to help MS clinicians respond more confidently when a patient reports suicidal thoughts.

The episode finishes with several additional stories worth checking out, including treatment discontinuation in older adults, EBV vaccine and T cell research, MS treatment sequencing, OCT in diagnosis, and the need for better pain care.

Featured stories

Researchers use lab grown mini brains to study MS repair

Sheffield treats its first MS participant with CAR T cell therapy

Cleveland Clinic revises its suicidal ideation protocol for MS care

More stories worth checking out

Stopping disease modifying therapies in older, stable patients

EBV vaccine and T cell trials in MS

Framework for sequencing MS treatments

OCT and the updated McDonald diagnostic criteria

Why MS pain needs more attention

Visit Just Multiple Sclerosis for the always open MS news stream, past weekly editions, community updates, and Sudoku Omega, a free sudoku game I built to help you slow down, focus, and relax.

Follow Just Multiple Sclerosis on Instagram and Facebook for weekly clips, updates, and community highlights.

Mental Health and Crisis Support

United States: Call or text 988 to reach the 988 Suicide & Crisis Lifeline. Free, confidential support is available 24 hours a day across the United States and its territories. 

Canada: Call or text 988 to reach the 9-8-8 Suicide Crisis Helpline. Support is available nationwide, 24 hours a day, in English and French. Visit 988.ca.

Other countries: Find verified crisis and emotional-support services in your country through Find A Helpline or Befrienders Worldwide. 

If someone is in immediate danger, contact local emergency services.

The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.

www.justmultiplesclerosis.com

Send us Fan Mail

This week on Just MS News, we lead with encouraging—but still early remyelination research.

Scientists have identified an experimental small molecule that promoted oligodendrocyte development and remyelination in preclinical models. We explain how this candidate differs from PTD802, the remyelination therapy we recently covered as it prepared to enter human testing.

We also look at:

• Fampridine becoming routinely available through NHS England for eligible adults with MS-related walking difficulties

• Evidence examining whether treatment escalation after clinically silent MRI lesions may reduce future relapse risk

• New research exploring how anti-CD20 therapies may affect protective immune cells originating in the gut

• A large U.S. analysis identifying racial, geographic and age-related disparities in MS-associated mortality

• Two brothers continuing their remarkable marathon journey using an adaptive racing wheelchair

ARTICLES AND SOURCES

1. A Novel Small Molecule Remyelination Therapy for Multiple Sclerosis
   Source: npj Drug Discovery
   https://www.nature.com/articles/s44386-026-00060-7

2. Thousands With MS to Get Fampridine on the NHS to Help Them Walk More Freely
   Source: NHS England
   https://www.england.nhs.uk/2026/07/thousands-ms-life-changing-drug-nhs-help-walk-more-freely/

Clinical commissioning policy:
https://www.england.nhs.uk/publication/clinical-commissioning-policy-prolonged-released-pr-fampridine-as-a-treatment-of-adults-with-multiple-sclerosis-and-associated-walking-impairment/

3. Treatment Escalation After Clinically Silent MRI Lesions in Relapsing-Remitting Multiple Sclerosis
   Source: Brain
   https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awag252/8741305

4. Anti-CD20 B-Cell Depletion Is Associated With Elevated Mucosal-Originating Circulating Immune Cells
   Source: Science Translational Medicine
   https://www.science.org/doi/10.1126/scitranslmed.aee1580

5. Racial and Ethnic Trends and Comorbidity Patterns in Multiple Sclerosis Mortality
   Source: Neurology Open Access
   https://www.neurology.org/doi/10.1212/WN9.0000000000000148

6. Man With MS Does Marathons With a Push From His Brother
   Source: Deseret News
   https://www.deseret.com/sports/2026/07/22/deseret-news-marathon-brian-danny-connolly-wheelchair-ms-people-with-disabilities/

Just MS News provides accessible summaries of multiple sclerosis news and research. This episode is for informational purposes and should not replace guidance from your healthcare team.

Visit Just Multiple Sclerosis:
https://www.justmultiplesclerosis.com

Listen to the podcast:
https://www.justmultiplesclerosis.com/podcast

#MultipleSclerosis #MSNews #Remyelination #MSResearch #Fampridine #MultipleSclerosisResearch

The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.

www.justmultiplesclerosis.com

Send us Fan Mail

This week on Just MS News, we lead with encouraging, but still early remyelination research.

Scientists have identified an experimental small molecule that promoted oligodendrocyte development and remyelination in preclinical models. We explain how this candidate differs from PTD802, the remyelination therapy we recently covered as it prepared to enter human testing.

We also look at:

• Fampridine becoming routinely available through NHS England for eligible adults with MS-related walking difficulties

• Evidence examining whether treatment escalation after clinically silent MRI lesions may reduce future relapse risk

• New research exploring how anti-CD20 therapies may affect protective immune cells originating in the gut

• A large U.S. analysis identifying racial, geographic and age-related disparities in MS-associated mortality

• Two brothers continuing their remarkable marathon journey using an adaptive racing wheelchair

ARTICLES AND SOURCES

1. A Novel Small Molecule Remyelination Therapy for Multiple Sclerosis
   Source: npj Drug Discovery
   https://www.nature.com/articles/s44386-026-00060-7
2. Thousands With MS to Get Fampridine on the NHS to Help Them Walk More Freely
   Source: NHS England
   https://www.england.nhs.uk/2026/07/thousands-ms-life-changing-drug-nhs-help-walk-more-freely/

Clinical commissioning policy:
https://www.england.nhs.uk/publication/clinical-commissioning-policy-prolonged-released-pr-fampridine-as-a-treatment-of-adults-with-multiple-sclerosis-and-associated-walking-impairment/

1. Treatment Escalation After Clinically Silent MRI Lesions in Relapsing-Remitting Multiple Sclerosis
   Source: Brain
   https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awag252/8741305
2. Anti-CD20 B-Cell Depletion Is Associated With Elevated Mucosal-Originating Circulating Immune Cells
   Source: Science Translational Medicine
   https://www.science.org/doi/10.1126/scitranslmed.aee1580
3. Racial and Ethnic Trends and Comorbidity Patterns in Multiple Sclerosis Mortality
   Source: Neurology Open Access
   https://www.neurology.org/doi/10.1212/WN9.0000000000000148
4. Man With MS Does Marathons With a Push From His Brother
   Source: Deseret News
   https://www.deseret.com/sports/2026/07/22/deseret-news-marathon-brian-danny-connolly-wheelchair-ms-people-with-disabilities/

Just MS News provides accessible summaries of multiple sclerosis news and research. This episode is for informational purposes and should not replace guidance from your healthcare team.

Visit Just Multiple Sclerosis:
https://www.justmultiplesclerosis.com

Listen to the podcast:
https://www.justmultiplesclerosis.com/podcast

#MultipleSclerosis #MSNews #Remyelination #MSResearch #Fampridine #MultipleSclerosisResearch

The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.

www.justmultiplesclerosis.com

Send us Fan Mail

This week on Just MS News, we examine new research that may help clarify how Epstein–Barr virus fits into the immune process behind multiple sclerosis.

We also look at evidence supporting earlier high-efficacy treatment for pediatric-onset MS, the DOT-MS trial on stopping treatment after years of stable disease, virtual-reality rehabilitation for cognitive symptoms, and a Colorado community story about mobility, rehabilitation and assistive technology.

This episode covers:

• A more specific EBV-reactive T-cell response identified in people with untreated MS
• Earlier high-efficacy treatment and long-term disability outcomes in pediatric MS
• What happened when people with stable MS stopped certain disease-modifying therapies
• Virtual-reality rehabilitation for cognition and mood
• A bride with MS who prepared for a supported 68-foot aisle walk

Articles and Research

CD4+ T Cells Reactive to Epstein–Barr Virus Late Lytic Antigens Are Enriched in Individuals With Multiple Sclerosis
Source: Science Translational Medicine
Authors: Kjetil Bjornevik and colleagues
Read the study

Early High-Efficacy Therapy May Reduce Disability in Pediatric MS
Source: Neurology Advisor
Based on research published in Neurology
Read the article

Discontinuation of Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis—Clinical Trial of the Year
Source: JAMA Neurology
Author: S. Andrew Josephson, MD
Read the editorial

Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial
Source: JAMA Neurology
Authors: Eline M. E. Coerver, Wing Hee Fung, Janet de Beukelaar and colleagues
Read the original trial

Effects of Virtual Reality-Based Rehabilitation on Cognitive Function and Mood in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Source: Multiple Sclerosis and Related Disorders
Authors: Jiongliang Zhang, Minmin Wu, Jinting Li, Wenjing Song, Xiaoguang Lin and Luwen Zhu
Read the study on PubMed

Colorado Bride With MS Surprises Wedding Guests by Walking Down the Aisle
Source: 9NEWS Colorado
Read the story

Visit Just Multiple Sclerosis for the complete weekly digest:
https://justmultiplesclerosis.com

Subscribe for calm, clear and accessible weekly MS news without the information overload.

#MultipleSclerosis #MSNews #JustMSNews #MSResearch #EpsteinBarrVirus #PediatricMS #MSRehabilitation

The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.

www.justmultiplesclerosis.com

Send us Fan Mail

This week on the Just MS Show, we look at five important multiple sclerosis stories.

Researchers used artificial intelligence to identify gray matter lesions that can be difficult to see on standard MRI scans. We also examine a head-to-head trial comparing rituximab with Ocrevus in newly diagnosed relapsing MS.

Other stories include the completion of enrollment in a nasal foralumab trial for non-active secondary progressive MS, early research into how myelin damage may affect brain activity during sleep, and a $500,000 gift supporting MS research from Las Vegas Raiders quarterback Fernando Mendoza and his family.

The Just MS Show delivers calm, clear and accessible MS news without hype or information overload.

Show Notes

AI reveals previously hidden gray matter lesions in MS

Researchers developed an artificial intelligence method that can identify cortical lesions that are often difficult to see on conventional MRI scans.

Read the article from News-Medical

Rituximab compares closely with Ocrevus in early relapsing MS trial

The OVERLORD-MS trial compared rituximab with Ocrevus in people with newly diagnosed relapsing MS and found rituximab was noninferior for preventing new or enlarging MRI lesions during the study period.

Read the article from Conexiant Neurology

Final participant begins treatment in nasal foralumab trial for non-active SPMS

Enrollment is complete in the Phase 2 INFORM-MS trial studying intranasal foralumab in people with non-active secondary progressive MS. Full safety and effectiveness results have not yet been released.

Read the article from NR Times

Myelin damage may alter brain rhythms during sleep

Early research suggests that damaged myelin may affect electrical brain activity during sleep. The strongest evidence currently comes from animal research, with further human studies still needed.

Read the article from News-Medical

Mendoza family presents $500,000 gift for MS research

Las Vegas Raiders quarterback Fernando Mendoza and his family formally presented a $500,000 gift supporting MS research at the University of Miami in honour of his mother, Elsa, who lives with MS.

Read the article from 8 News NOW

Links

Just MS News:
https://www.justmultiplesclerosis.com

Podcast page:
https://www.justmultiplesclerosis.com/podcast

Weekly news archive:
https://www.justmultiplesclerosis.com/archive

The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.

www.justmultiplesclerosis.com

Send us Fan Mail

This week’s Just MS News starts with two stories from the same MS brain-donor study, looking at why progression can differ so much from person to person. We also cover MS Copilot and digital disability monitoring, research into fat-filled immune cells called foamy microglia, an experimental brain implant for speech loss, and Spain’s “Get Wet for MS” campaign supporting neurorehabilitation and research.

As always, this update is designed to give the MS community one calm place to catch up on the week’s most relevant news without hype or overload.

Live article links

1. Large multiple sclerosis brain cohort reveals biological differences linked to disease severity
   https://medicalxpress.com/news/2026-06-large-multiple-sclerosis-brain-cohort.html
2. Brain Tissue Patterns and Genetics Drive MS Progression
   https://neurosciencenews.com/multiple-sclerosis-progression-genetics-30961/
3. EAN 2026: MS Copilot shows promise in monitoring disability progression in MS
   https://www.clinicaltrialsarena.com/analyst-comment/ean-2026-ms-copilot-shows-promise-in-monitoring-disability-progression-in-ms/
4. Fat-filled immune cells may help explain why some MS progresses faster
   https://www.diabetes.co.uk/news/2026/jul/fat-filled-immune-cells-may-help-explain-why-some-ms-progresses-faster.html
5. New brain implant could restore communication for people with speech loss
   https://www.news-medical.net/news/20260629/New-brain-implant-could-restore-communication-for-people-with-speech-loss.aspx
6. Promote neurorehabilitation and research, challenges of “Mójate por la Esclerosis Múltiple” 2026
   https://www.democrata.es/en/health/promote-neurorehabilitation-and-research-challenges-of-mojate-por-la-esclerosis-multiple-2026/

The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.

www.justmultiplesclerosis.com

Send us Fan Mail

This week on Just MS News, we reviewed 139 MS-related articles from June 22–28, 2026, and narrowed them down to the stories most worth your time.

The lead story this week is early, but meaningful: PTD802, an oral remyelination therapy, has been cleared for its first human trial. It is not an approved treatment, and it is not a cure. But for people living with MS, research focused on myelin repair is worth paying attention to.

We also cover Sanofi’s Cenrifki, also known as tolebrutinib, being approved in Europe for adults with non-relapsing secondary progressive MS. This is one of the biggest confirmed treatment stories of the week, especially for progressive MS, but it also comes with important safety monitoring.

Other stories this week include blood-based NfL testing for MS monitoring, early high-efficacy treatment in childhood-onset MS, light therapy glasses for MS-related fatigue, menopause and cognition, balance training, cognitive coaching, ocrelizumab and rituximab infection-risk research, vision recovery research, and a human story from the National MS Society called “From Patient to Researcher: How MS Changed My Path.”

As always, this is not medical advice. Just MS News is a calm weekly recap meant to help people living with MS, caregivers, advocates, and supporters understand what is happening in MS news without the overload.

1. PTD802 oral remyelination therapy
   https://www.neurologylive.com/view/fda-clears-investigational-new-drug-application-remyelinating-agent-ptd802-multiple-sclerosis
2. Cenrifki approved in Europe for non-relapsing SPMS
   https://pmlive.com/sanofis-cenrifki-approved-in-europe-for-secondary-progressive-ms-without-relapses/
3. Blood-based NfL testing and MS monitoring
   https://www.technologynetworks.com/tn/blog/how-blood-based-nfl-testing-could-transform-multiple-sclerosis-management-414010
4. Early high-efficacy treatment in children with MS
   https://www.msaustralia.org.au/news/early-treatment-with-highly-effective-therapy-could-reduce-long-term-disability-in-children-with-ms/
5. Light therapy glasses for MS fatigue
   https://www.nature.com/articles/s41598-026-56950-3
6. Menopause and MS cognition
   https://www.neurologyadvisor.com/features/menopause-and-multiple-sclerosis-neurologic-manifestations/
7. Balance training for MS
   https://clinician.nejm.org/balance-training-multiple-sclerosis-nejm-jw.NA46017
8. Mindset coaching for MS cognitive symptoms
   https://multiplesclerosisnewstoday.com/news-posts/2026/06/22/trial-target-ms-cognitive-symptoms-mindset-coaching/
9. Ocrelizumab and rituximab serious infection risk
   https://verahealth.ai/fr/news/multiple-sclerosis-ocrelizumab-and-rituximab-show-similar-serious-infection-risk
10. Vision recovery research
    https://iovs.arvojournals.org/article.aspx?articleid=2814516
11. From Patient to Researcher: How MS Changed My Path
    https://www.nationalmssociety.org/news-and-magazine/momentum-magazine/from-the-community/from-patient-to-researcher-ms-changed-my-path

The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.

www.justmultiplesclerosis.com

Send us Fan Mail

This week on Just MS News, we look at nine MS stories from the week of June 15–21, 2026.

Topics include hidden cognitive symptoms, brain atrophy research, cognitive testing and daily life, accessible travel, progression independent of relapse activity, PFAS exposure, vaccine safety, mobility technology, and early repair-focused stem cell research.

Just MS News is built to help the MS community cut through the noise and follow the stories that matter.

Covered this week:

1. UB research targets hidden symptoms of multiple sclerosis
   https://www.buffalo.edu/ubnow/stories/2026/06/benedict-hidden-symptoms-ms.html
2. Untangling Brain Atrophy in MS
   https://www.nationalmssociety.org/news-and-magazine/momentum-magazine/research-and-science/untangling-brain-atrophy-in-ms
3. Can Cognitive Tests Predict Daily Life With MS? The Answer Is Yes, But Not Perfectly
   https://www.zmescience.com/science/news-science/can-cognitive-tests-predict-daily-life-with-ms-the-answer-is-yes-but-not-perfectly/
4. 10 MS Accessible Travel Planning Tips
   https://www.nationalmssociety.org/news-and-magazine/momentum-magazine/living-well/plan-an-accessible-escape
5. Comorbidities for Predicting Progression Independent of Relapse Activity in Multiple Sclerosis Treated With B-Cell Depletion
   https://pubmed.ncbi.nlm.nih.gov/42226439/
6. PFAS “forever chemicals” may be linked to multiple sclerosis, especially in women
   https://usrtk.org/healthwire/pfas-forever-chemicals-linked-to-multiple-sclerosis-especially-in-women/
7. Measles, chickenpox vaccines not tied to relapse in people with multiple sclerosis
   https://www.cidrap.umn.edu/measles/measles-chickenpox-vaccines-not-tied-relapse-people-multiple-sclerosis
8. Paralyzed Minnesota man’s invention aims to help people with mobility issues walk again
   https://www.cbsnews.com/minnesota/news/walkport-invention-mobility-issues/
9. NewcelX Stem Cell Platform Strengthened by Peer-Reviewed AstroRx Study in Multiple Sclerosis
   https://www.tipranks.com/news/company-announcements/newcelx-stem-cell-platform-strengthened-by-peer-reviewed-astrorx-study-in-multiple-sclerosis

One week of MS news. One calm place.

The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.

www.justmultiplesclerosis.com